Kailera Therapeutics, Inc.’s Lock-Up Period Will Expire on October 14th (NASDAQ:KLRA)

Kailera Therapeutics’ (NASDAQ:KLRA) lock-up period will end on Wednesday, October 14th. Kailera Therapeutics had issued 39,062,500 shares in its public offering on April 17th. The total size of the offering was $625,000,000 based on an initial share price of $16.00. After the expiration of Kailera Therapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Kailera Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.75.

Kailera Therapeutics Price Performance

KLRA stock opened at $10.00 on Friday. The firm has a market capitalization of $1.30 billion and a P/E ratio of -0.00. Kailera Therapeutics has a twelve month low of $9.76 and a twelve month high of $28.23. The company has a 50 day moving average price of $15.14.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, equities research analysts expect that Kailera Therapeutics will post -3.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Kailera Therapeutics

Several hedge funds have recently made changes to their positions in KLRA. State Street Corp acquired a new position in Kailera Therapeutics in the 2nd quarter valued at about $19,126,000. Tidal Investments LLC purchased a new stake in Kailera Therapeutics during the 2nd quarter valued at approximately $309,000. Squarepoint Ops LLC acquired a new stake in Kailera Therapeutics during the 2nd quarter worth approximately $993,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Kailera Therapeutics in the second quarter valued at approximately $24,233,000. Finally, Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics in the second quarter valued at approximately $113,923,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions.

Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.